CTOs on the Move

Jasper Clinical Research and Development

www.jasperclinic.biz

 
Jasper Clinical Research and Development, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Nereid Therapeutics

Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and resulting biomolecular condensates.

Applied Technology Holdings

ATH's sales and technology groups build custom wireless turn-key technology solutions that relate to specific customer body motion measurement needs and market opportunities. ATH's vision is to commercialize it's patent portfolio and lead the industry in distributed wireless bioMotion technology and data capture processes. Founded in 2005, Applied Technology Holdings Inc., is a hardware and software maker specializing in wireless bioMotion monitoring systems for medical, sports, gaming, military and aviation applications. ATH's subsidiaries are experts in supporting the solution provider platforms for easy integration into the target markets. Other ATH companies participate in the Sports, Medical, Gaming, Aviation, and Military market opportunities and segments.

Limerick BioPharma

Limerick BioPharma, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lerner Research Institute

Cleveland Clinic`s rich history includes continuous emphasis on research and innovation. In 1921, the founders stated their commitment not only to treating disease and educating the next generations of healers, but also to researching the causes of disease. They realized that understanding the biological basis of disease is necessary to developing new diagnostics and therapeutics.

MBX Biosciences

MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.